DL-3,4-dihydroxyphenylglycine | 859451-00-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: DL-3,4-dihydroxyphenylglycine
• 英文别名: 3,4-dihydroxyphenyl-glycine；D-3,4-Dihydroxyphenylglycine；3,4-dihydroxy-D-phenylglycine；(3,4-Dihydroxyphenyl)glycine；2-(3,4-dihydroxyanilino)acetic acid
• CAS: 859451-00-6
• 化学式: C₈H₉NO₄
• 分子量: 183.164
• InChiKey: RXSPMCUQMQOINZ-UHFFFAOYSA-N

物化性质

• 熔点：
  204-206 °C
• 沸点：
  521.2±50.0 °C(Predicted)
• 密度：
  1.567±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  89.8
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  DL-3,4-dihydroxyphenylglycine 以70%的产率得到D-2-[(4-Ethyl-2,3-dioxopiperazin-1-yl)carbonylamino]-2-(3,4-dihydroxyphenyl)acetic acid
  参考文献：
  名称：

  .beta.-Lactam antibacterial agents

  摘要：

  具有β-内酰胺环上与羰基相邻的碳原子上的α-甲酰氨基取代基的β-内酰胺类抗生素，特别是具有部分结构的双环化合物：##STR1## 进一步揭示了制备这些化合物的中间体和过程。

  公开号：

  US04539149A1
• 作为产物：
  描述：

  sodium glyoxylate 、 乙酸铵 、 邻苯二酚 以 水 为溶剂， 以11.0 g of DL-(3,4-dihydroxyphenyl)glycine are thereby obtained as crystals的产率得到DL-3,4-dihydroxyphenylglycine
  参考文献：
  名称：

  Process for preparing a hydroxyphenylglycine compound

  摘要：

  甘醛酸或其盐，有机或无机酸的铵盐和公式为##STR1##的苯酚化合物缩合制备羟基苯基甘氨酸化合物，其中n为1至3的整数。因此获得的羟基苯基甘氨酸化合物在合成青霉素和头孢菌素的中间体中有用。

  公开号：

  US04175206A1

文献信息

• .beta.-Lactam antibiotics
  申请人：Beecham Group p.l.c.

  公开号：US04540688A1

  公开（公告）日：1985-09-10

  Compounds of formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof have antibacterial activity: ##STR1## wherein R is hydrogen, C.sub.1-6 alkylcarbonyl or C.sub.1-6 alkyl; R.sup.1 is hydrogen or hydrocarbon; R.sup.2 is hydrogen, or optionally substituted hydrocarbon or optionally substituted heterocyclyl or CXR.sup.d, where X is O or S and R.sup.d is hydrogen or optionally substituted hydrocarbon or optionally substituted heterocyclyl; or R.sup.1 and R.sup.2 together with the nitrogen to which they are attached, form an optionally substituted heterocyclyl group. A process for the preparation of such compounds and compositions comprising them, are also described.

  化合物的结构式（I）或其药学上可接受的盐或体内水解酯具有抗菌活性：##STR1##其中R为氢，C.sub.1-6烷基羰基或C.sub.1-6烷基；R.sup.1为氢或碳氢化合物；R.sup.2为氢，或可选择地取代的碳氢化合物或可选择地取代的杂环烷基或CXR.sup.d，其中X为O或S，R.sup.d为氢或可选择地取代的碳氢化合物或可选择地取代的杂环烷基；或R.sup.1和R.sup.2与它们连接的氮一起形成可选择地取代的杂环烷基基团。还描述了制备这类化合物和包含它们的组合物的方法。
• Substituted vinyl cephalosporins
  申请人：Bristol-Myers Company

  公开号：US04520022A1

  公开（公告）日：1985-05-28

  3-[(Z)-1-Propen-1-yl]-7-acylamido cephalosporins in which the 7-acyl group is phenylglycyl or substituted phenylglycyl are orally active antibiotics against Gram+ and Gram- bacteria.

  3-[(Z)-1-丙烯基]-7-酰胺头孢菌素，其中7-酰基为苯甘氨基或取代苯甘氨基，是针对革兰氏阳性和阴性细菌的口服活性抗生素。
• .beta.-thiopropionyl-aminoacid derivatives and their use as
  申请人：SmithKline Beecham p.l.c.

  公开号：US06048852A1

  公开（公告）日：2000-04-11

  A method of treatment of bacterial infections in humans or animals which comprises administering, in combination with a .beta.-lactam antibiotic, a therapeutically effective amount of an amino acid derivative of Formula (I) or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof, ##STR1## wherein: R is hydrogen, a salt forming cation or an in vivo hydrolysable ester-forming group; R.sub.1 is hydrogen, (C.sub.1-6)alkyl optionally substituted by up to three halogen atoms or by a mercapto, (C.sub.1-6)alkoxy, hydroxy, amino, nitro, carboxy, (C.sub.1-6)alkylcarbonyloxy, (C.sub.1-6)alkoxycarbonyl, formyl or (C.sub.1-6)alkylcarbonyl group, (C.sub.3-7)cycloalkyl, (C.sub.3-7)cycloalkyl(C.sub.2-6)alkyl, (C.sub.2-6)alkenyl, (C.sub.2-6)alkynyl, aryl, aryl(C.sub.1-6)alkyl, heterocyclyl or heterocyclyl(C.sub.1-6)alkyl; R.sub.2 is hydrogen, (C.sub.1-6)alkyl or aryl(C.sub.1-6)alkyl; R.sub.3 is hydrogen, (C.sub.1-6)alkyl optionally substituted by up to three halogen atoms, (C.sub.3-7)cycloalkyl, fused aryl(C.sub.3-7)cycloalkyl, (C.sub.3-7)cycloalkyl(C.sub.2-6)alkyl, (C.sub.2-6)alkenyl, (C.sub.2-6)alkynyl, aryl, aryl-(CHR.sub.10).sub.m --X--(CHR.sub.11).sub.n, heterocyclyl or heterocyclyl-(CHR.sub.10).sub.m --X--(CHR.sub.11).sub.n, where m is 0 to 3, n is 1 to 3, each R.sub.10 and R.sub.11 is independently hydrogen or (C.sub.1-4)alkyl and X is O, S(O).sub.x where x is 0-2, or a bond; R.sub.4 is hydrogen, or an in vivo hydrolysable acyl group; and R.sub.5 and R.sub.6 are independently hydrogen and (C.sub.1-6)alkyl or together represent (CH.sub.2).sub.p where p is 2 to 5. Some compounds are claimed per se.

  一种治疗人类或动物细菌感染的方法，包括与β-内酰胺类抗生素联合给药，给予公式(I)的氨基酸衍生物的治疗有效量或其药用可接受的盐、溶剂化合物或体内可水解酯的治疗有效量，其中：R为氢、形成盐的阳离子或体内可水解酯形成基团；R.sub.1为氢、(C.sub.1-6)烷基，可选地被高达三个卤素原子或巯基、(C.sub.1-6)烷氧基、羟基、氨基、硝基、羧基、(C.sub.1-6)烷基羰氧基、(C.sub.1-6)烷氧羰基、甲酰基或(C.sub.1-6)烷基羰基取代，(C.sub.3-7)环烷基，(C.sub.3-7)环烷基(C.sub.2-6)烷基，(C.sub.2-6)烯基，(C.sub.2-6)炔基，芳基，芳基(C.sub.1-6)烷基，杂环烷基或杂环烷基(C.sub.1-6)烷基；R.sub.2为氢，(C.sub.1-6)烷基或芳基(C.sub.1-6)烷基；R.sub.3为氢，(C.sub.1-6)烷基，可选地被高达三个卤素原子取代，(C.sub.3-7)环烷基，融合的芳基(C.sub.3-7)环烷基，(C.sub.3-7)环烷基(C.sub.2-6)烷基，(C.sub.2-6)烯基，(C.sub.2-6)炔基，芳基，芳基-(CHR.sub.10).sub.m --X--(CHR.sub.11).sub.n，杂环烷基或杂环烷基-(CHR.sub.10).sub.m --X--(CHR.sub.11).sub.n，其中m为0至3，n为1至3，每个R.sub.10和R.sub.11独立地为氢或(C.sub.1-4)烷基，X为O，S(O).sub.x，其中x为0-2，或键；R.sub.4为氢，或体内可水解的酰基；R.sub.5和R.sub.6独立地为氢和(C.sub.1-6)烷基，或一起代表(CH.sub.2).sub.p，其中p为2至5。一些化合物本身被要求。
• Racemization of optically active 2-substituted phenyl glycine esters
  申请人：——

  公开号：US20040073057A1

  公开（公告）日：2004-04-15

  A process for preparing racemic mixtures containing nearly equal amounts of stereo isomers of compounds of formula (I), or their salts, by heating an enantiomerically enriched material with thionyl chloride. 1 A required useful enantiomer may thereby be recovered from unwanted mother liquors that would otherwise be otherwise be discarded.

  一种制备含有化合物（I）的立体异构体近乎相等量的混合物或其盐的方法，通过将富集对映体的材料与氯化硫酰加热。因此，可以从否则将被丢弃的不需要的母液中回收所需的有用对映体。
• Highly homogeneous molecular markers for electrophoresis
  申请人：Invitrogen Corporation

  公开号：US20040014082A1

  公开（公告）日：2004-01-22

  The invention relates to marker molecules for identifying physical properties of molecular species separated by the use of electrophoretic systems. The invention further relates to methods for preparing and using marker molecules.

  这项发明涉及用于识别电泳系统分离的分子物种的物理性质的标记分子。该发明还涉及制备和使用标记分子的方法。